Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert Ferro

Showing results (31-40 of 127) with videos related to

Pageof 13
Sort By:
Prostaglandins & Other Lipid Mediators|April 15, 2015
Antiplatelet drug resistance: Molecular insights and clinical implicationsChristopher N Floyd, Albert Ferro
JRSM Cardiovascular Disease|November 1, 2013
The physician's role in prescribing physical activity for the prevention and treatment of essential hypertensionJohn H M Brooks, Albert Ferro
British Journal of Clinical Pharmacology|April 24, 2008
Pharmacogenetics of aspirin resistance: a comprehensive systematic reviewTimothy Goodman, Albert Ferro, Pankaj Sharma
Cardiovascular Research|July 26, 2015
Netrin-1 as a novel therapeutic target in cardiovascular disease: to activate or inhibit?Kerry Layne, Albert Ferro, Gabriella Passacquale
JRSM Cardiovascular Disease|March 28, 2020
The effectiveness of a specialist Hypertension Clinic in reducing blood pressure: Factors determining blood pressure responseGeorgina O'Callaghan, Mariam Butt, Albert Ferro
International Journal of Clinical Practice|March 30, 2007
The genetics of aspirin resistanceTimothy Goodman, Pankaj Sharma, Albert Ferro
Circulation Research|September 29, 2007
Platelet-derived nitric oxide signaling and regulationEugenia Gkaliagkousi, James Ritter, Albert Ferro
Clinical Pharmacokinetics|May 10, 2012
Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implicationsChristopher N Floyd, Gabriella Passacquale, Albert Ferro
Pharmacology & Therapeutics|June 14, 2003
The lipid and non-lipid effects of statinsAnthony S Wierzbicki, Robin Poston, Albert Ferro
Atherosclerosis|July 31, 2007
Whole body nitric oxide production is not decreased in patients with coronary atherosclerosis but is inversely related to plasma homocysteinePeter D O'Kane, Graham Jackson, Albert Ferro
Pageof 13

Showing results (31-40 of 127) with videos related to

Sort By:
Pageof 13
Prostaglandins & Other Lipid Mediators|April 15, 2015
Antiplatelet drug resistance: Molecular insights and clinical implicationsChristopher N Floyd, Albert Ferro
JRSM Cardiovascular Disease|November 1, 2013
The physician's role in prescribing physical activity for the prevention and treatment of essential hypertensionJohn H M Brooks, Albert Ferro
British Journal of Clinical Pharmacology|April 24, 2008
Pharmacogenetics of aspirin resistance: a comprehensive systematic reviewTimothy Goodman, Albert Ferro, Pankaj Sharma
Cardiovascular Research|July 26, 2015
Netrin-1 as a novel therapeutic target in cardiovascular disease: to activate or inhibit?Kerry Layne, Albert Ferro, Gabriella Passacquale
JRSM Cardiovascular Disease|March 28, 2020
The effectiveness of a specialist Hypertension Clinic in reducing blood pressure: Factors determining blood pressure responseGeorgina O'Callaghan, Mariam Butt, Albert Ferro
International Journal of Clinical Practice|March 30, 2007
The genetics of aspirin resistanceTimothy Goodman, Pankaj Sharma, Albert Ferro
Circulation Research|September 29, 2007
Platelet-derived nitric oxide signaling and regulationEugenia Gkaliagkousi, James Ritter, Albert Ferro
Clinical Pharmacokinetics|May 10, 2012
Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implicationsChristopher N Floyd, Gabriella Passacquale, Albert Ferro
Pharmacology & Therapeutics|June 14, 2003
The lipid and non-lipid effects of statinsAnthony S Wierzbicki, Robin Poston, Albert Ferro
Atherosclerosis|July 31, 2007
Whole body nitric oxide production is not decreased in patients with coronary atherosclerosis but is inversely related to plasma homocysteinePeter D O'Kane, Graham Jackson, Albert Ferro
Pageof 13